| Body: |
Managing Cytomegalovirus (CMV) infection in solid organ transplant recipients involves assessing patient risk based on serology status, transplant organ type, and immunosuppression levels. Treatment initiation thresholds vary depending on these individualized factors. Current strategies for refractory and resistant CMV infections include the use of Maribavir, supported by findings from the SOLSTICE trial demonstrating its efficacy and safety. Clinical management approaches discussed involve optimization of immunosuppression, genotypic testing for antiviral resistance, and treatment strategies for resistant CMV cases. Emerging developments such as new antiviral drugs, standardized resistance testing methods, and advanced immune monitoring techniques are identified as key areas for future improvement |
